CASI Pharmaceuticals Faces Nasdaq Delisting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CASI?
Source: seekingalpha
CASI Pharmaceuticals' stock fell significantly as it crossed below the 5-day SMA, reflecting investor concerns.
The company received a determination letter from Nasdaq regarding its delisting due to failure to meet continued listing requirements, with trading expected to be suspended on February 26, 2026. CASI has decided not to appeal this decision, indicating management's resignation regarding its financial situation. Following delisting, CASI's shares are expected to be quoted on the OTC market, which may impact investor liquidity and confidence.
This delisting notice highlights ongoing financial and operational difficulties for CASI Pharmaceuticals, raising concerns about its future financing capabilities and market competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CASI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CASI
Wall Street analysts forecast CASI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.207
Low
4.00
Averages
4.00
High
4.00
Current: 0.207
Low
4.00
Averages
4.00
High
4.00
About CASI
CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Company’s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Company’s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CASI Pharmaceuticals to Be Delisted from Nasdaq
- Delisting Notification: CASI Pharmaceuticals received a determination letter from the Nasdaq Hearings Panel on February 23, 2026, indicating that its securities will be delisted on February 26, 2026, due to failure to meet continued listing requirements, highlighting significant compliance challenges for the company.
- Market Transition: Although the company does not intend to request a review, its ordinary shares will move to the OTC market, with CASI cautioning that there is no guarantee brokers will maintain a market, potentially impacting liquidity and reflecting a lack of market confidence.
- R&D Progress: CASI remains focused on advancing CID-103, a fully human IgG1 monoclonal antibody for organ transplant rejection and autoimmune diseases, having received regulatory approvals for clinical trials in China and the U.S., demonstrating the company's ongoing commitment to research and development.
- Stock Price Volatility: CASI's stock closed at $0.21 on Wednesday, down 74.06%, but rose 34.94% to $0.28 in premarket trading on Thursday, indicating mixed market expectations regarding the company's future prospects.
See More
CASI Pharmaceuticals Plans Transition to OTC Markets After Nasdaq Delisting
- Nasdaq Delisting Decision: CASI Pharmaceuticals has been formally delisted by the Nasdaq Hearings Panel due to failure to meet continued listing requirements, with trading expected to be suspended at market open on Thursday, indicating significant compliance challenges for the company.
- Transition to OTC Markets: The company plans to quote its ordinary shares on OTC Markets Group, and while it claims the delisting has 'no significant impact' on operations, this transition may affect investor confidence and limit liquidity.
- Stock Price Volatility: CASI Pharmaceuticals has a market capitalization of $4.26 million, with a staggering 91.13% decline in stock price over the past 12 months, currently trading at $0.21, near its 52-week low, reflecting a severe market environment.
- Technical Indicators Warning: The Relative Strength Index (RSI) stands at 18.40, indicating the stock is oversold, and combined with a 74.06% drop in a single day, it highlights the intensifying negative sentiment surrounding the stock.
See More
U.S. Stocks Rise as TJX Reports Strong Earnings Beat
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 250 points, indicating improved market sentiment, particularly as technology shares increased by 1.6%, reflecting heightened investor confidence in the tech sector.
- TJX Earnings Report: TJX Companies reported fourth-quarter earnings of $1.43 per share, surpassing analyst expectations of $1.39, with sales reaching $17.743 billion, also exceeding the consensus estimate of $17.370 billion, showcasing the company's robust performance in retail.
- Future Outlook: Despite TJX's FY2027 GAAP EPS guidance of $4.93 to $5.02 falling short of the market estimate of $5.17, the strong quarterly results may still attract investor interest, reflecting the company's resilience in an uncertain market environment.
- Economic Data: The volume of mortgage applications in the U.S. increased by 0.4% in the third week of February, although this was lower than the previous week's 2.8% gain, indicating a gradual recovery in the housing market that could positively impact future economic growth.
See More
CASI Pharmaceuticals Faces Nasdaq Delisting Decision
- Stock Plunge: CASI Pharmaceuticals' shares plummeted over 64% in Wednesday's opening trade, reflecting a strong market reaction to the Nasdaq delisting decision, indicating a sharp decline in investor confidence that could lead to liquidity issues.
- Delisting Decision: Nasdaq determined that CASI failed to meet continued listing requirements, resulting in the suspension of trading on Thursday, with CASI stating it does not intend to appeal the decision, showcasing a negative outlook from the company.
- Market Transition: CASI expects its existing shares to trade on the OTC market, but the company cautioned that this transition is not guaranteed, suggesting potential instability and lack of transparency in future trading.
- R&D Progress: Despite the delisting challenges, CASI continues to advance its CID-103 development, aimed at treating organ transplant rejection and autoimmune diseases, demonstrating the company's ongoing commitment to its core business amidst poor stock performance.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 200 Points
- Strong Dow Performance: The Dow Jones index gained over 200 points on Wednesday, rising 0.41% to close at 49,375.99, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ surged 0.77% to 23,040.20, while the S&P 500 rose 0.55% to 6,928.15, reflecting strong performances in technology and other major sectors.
- Lowe's Earnings Beat Expectations: Lowe's reported Q4 earnings of $1.98 per share, exceeding analyst expectations of $1.94, with sales of $20.584 billion also surpassing the consensus estimate of $20.334 billion, although the company issued weaker future earnings guidance.
- Energy Stocks Decline: Energy stocks fell by 0.3% on Wednesday, contrasting with a 0.8% rise in information technology shares, indicating a divergence in market performance that could influence investor asset allocation strategies.
See More
CASI PHARMACEUTICALS ANTICIPATES LISTING OF ORDINARY SHARES ON OTC MARKET RUN BY OTC MARKETS GROUP INC.
Company Announcement: Casi Pharmaceuticals is set to quote its ordinary shares on the "over-the-counter" market.
Market Operations: The trading will be facilitated by OTC Markets Group Inc.
See More
CASI Pharmaceuticals to Be Delisted from Nasdaq
- Delisting Notification: CASI Pharmaceuticals received a determination letter from the Nasdaq Hearings Panel on February 23, 2026, indicating that its securities will be delisted on February 26, 2026, due to failure to meet continued listing requirements, highlighting significant compliance challenges for the company.
- Market Transition: Although the company does not intend to request a review, its ordinary shares will move to the OTC market, with CASI cautioning that there is no guarantee brokers will maintain a market, potentially impacting liquidity and reflecting a lack of market confidence.
- R&D Progress: CASI remains focused on advancing CID-103, a fully human IgG1 monoclonal antibody for organ transplant rejection and autoimmune diseases, having received regulatory approvals for clinical trials in China and the U.S., demonstrating the company's ongoing commitment to research and development.
- Stock Price Volatility: CASI's stock closed at $0.21 on Wednesday, down 74.06%, but rose 34.94% to $0.28 in premarket trading on Thursday, indicating mixed market expectations regarding the company's future prospects.
See More
CASI Pharmaceuticals Plans Transition to OTC Markets After Nasdaq Delisting
- Nasdaq Delisting Decision: CASI Pharmaceuticals has been formally delisted by the Nasdaq Hearings Panel due to failure to meet continued listing requirements, with trading expected to be suspended at market open on Thursday, indicating significant compliance challenges for the company.
- Transition to OTC Markets: The company plans to quote its ordinary shares on OTC Markets Group, and while it claims the delisting has 'no significant impact' on operations, this transition may affect investor confidence and limit liquidity.
- Stock Price Volatility: CASI Pharmaceuticals has a market capitalization of $4.26 million, with a staggering 91.13% decline in stock price over the past 12 months, currently trading at $0.21, near its 52-week low, reflecting a severe market environment.
- Technical Indicators Warning: The Relative Strength Index (RSI) stands at 18.40, indicating the stock is oversold, and combined with a 74.06% drop in a single day, it highlights the intensifying negative sentiment surrounding the stock.
See More
U.S. Stocks Rise as TJX Reports Strong Earnings Beat
- Market Performance: U.S. stocks broadly rose on Wednesday, with the Nasdaq Composite gaining over 250 points, indicating improved market sentiment, particularly as technology shares increased by 1.6%, reflecting heightened investor confidence in the tech sector.
- TJX Earnings Report: TJX Companies reported fourth-quarter earnings of $1.43 per share, surpassing analyst expectations of $1.39, with sales reaching $17.743 billion, also exceeding the consensus estimate of $17.370 billion, showcasing the company's robust performance in retail.
- Future Outlook: Despite TJX's FY2027 GAAP EPS guidance of $4.93 to $5.02 falling short of the market estimate of $5.17, the strong quarterly results may still attract investor interest, reflecting the company's resilience in an uncertain market environment.
- Economic Data: The volume of mortgage applications in the U.S. increased by 0.4% in the third week of February, although this was lower than the previous week's 2.8% gain, indicating a gradual recovery in the housing market that could positively impact future economic growth.
See More
CASI Pharmaceuticals Faces Nasdaq Delisting Decision
- Stock Plunge: CASI Pharmaceuticals' shares plummeted over 64% in Wednesday's opening trade, reflecting a strong market reaction to the Nasdaq delisting decision, indicating a sharp decline in investor confidence that could lead to liquidity issues.
- Delisting Decision: Nasdaq determined that CASI failed to meet continued listing requirements, resulting in the suspension of trading on Thursday, with CASI stating it does not intend to appeal the decision, showcasing a negative outlook from the company.
- Market Transition: CASI expects its existing shares to trade on the OTC market, but the company cautioned that this transition is not guaranteed, suggesting potential instability and lack of transparency in future trading.
- R&D Progress: Despite the delisting challenges, CASI continues to advance its CID-103 development, aimed at treating organ transplant rejection and autoimmune diseases, demonstrating the company's ongoing commitment to its core business amidst poor stock performance.
See More
U.S. Stocks Rise in Morning Trading, Dow Jones Up Over 200 Points
- Strong Dow Performance: The Dow Jones index gained over 200 points on Wednesday, rising 0.41% to close at 49,375.99, indicating positive market sentiment and increased investor confidence.
- NASDAQ and S&P 500 Rise: The NASDAQ surged 0.77% to 23,040.20, while the S&P 500 rose 0.55% to 6,928.15, reflecting strong performances in technology and other major sectors.
- Lowe's Earnings Beat Expectations: Lowe's reported Q4 earnings of $1.98 per share, exceeding analyst expectations of $1.94, with sales of $20.584 billion also surpassing the consensus estimate of $20.334 billion, although the company issued weaker future earnings guidance.
- Energy Stocks Decline: Energy stocks fell by 0.3% on Wednesday, contrasting with a 0.8% rise in information technology shares, indicating a divergence in market performance that could influence investor asset allocation strategies.
See More
CASI PHARMACEUTICALS ANTICIPATES LISTING OF ORDINARY SHARES ON OTC MARKET RUN BY OTC MARKETS GROUP INC.
Company Announcement: Casi Pharmaceuticals is set to quote its ordinary shares on the "over-the-counter" market.
Market Operations: The trading will be facilitated by OTC Markets Group Inc.
See More
